Panacea Biotec (BOM:531349) Marketable Securities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531349 Panacea Biotec Ltd BOM:531349
63 GF Score
Price ₹388.35
GF Value ₹404.52
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Panacea Biotec Marketable Securities?

Panacea Biotec BOM:531349 -1.36% 63 Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:531349 with a GF Score™ of 63/100 and a GF Value™ of ₹404.52 (Fairly Valued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Panacea Biotec's Marketable Securities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Panacea Biotec's annual Marketable Securities declined from Mar. 2024 (₹1,267 Mil) to Mar. 2025 (₹717 Mil) but then increased from Mar. 2025 (₹717 Mil) to Mar. 2026 (₹774 Mil).

Panacea Biotec  (BOM:531349) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Panacea Biotec Marketable Securities Related Terms

Panacea Biotec Marketable Securities Historical Data

* Premium members only.

The historical data trend for Panacea Biotec's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Biotec Marketable Securities Chart

Panacea Biotec Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,012.78 1,731.97 1,266.63 717.10 773.50

Panacea Biotec Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 646.80 0.00 773.50 0.00
BOM:531349
63GF Score
Panacea Biotec Ltd BOM:531349
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panacea Biotec Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0 Mil mean?
Panacea Biotec (BOM:531349) has a Marketable Securities of ₹0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Panacea Biotec and its competitors.
Is Panacea Biotec's Marketable Securities too high?
Panacea Biotec's current Marketable Securities is ₹0 Mil. Overall, Panacea Biotec has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's Marketable Securities compare to VRTX and REGN?
Panacea Biotec's Marketable Securities of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Panacea Biotec and its competitors. Panacea Biotec's current Marketable Securities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Fairly Valued. The stock's GF Value™ is ₹404.52, compared to a current price of ₹388.35 — trading 4% below its estimated fair value. The current Marketable Securities is ₹0 Mil. Panacea Biotec's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panacea Biotec (BOM:531349) Overvalued in 2026?

Based on GuruFocus' analysis, Panacea Biotec stock appears to be undervalued. The current stock price of ₹388.35 is trading 4% below its estimated GF Value™ of ₹404.52. GuruFocus considers Panacea Biotec to be Fairly Valued.

Key valuation signals for BOM:531349:

  • Marketable Securities: ₹0 Mil
  • GF Value™: ₹404.52 vs. price of ₹388.35 (4% below fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Panacea Biotec Business Description

Other Exchanges PANACEABIO:India
Address Mathura Road, B-1 Extension/G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
63GF Score

Get the complete analysis for BOM:531349

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹388.35
Price
₹404.52
GF Value